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CLINICAL INVESTIGATION Prostate
HIGH-DOSE-RATE INTERSTITIAL BRACHYTHERAPY AS A MONOTHERAPY
FOR LOCALIZED PROSTATE CANCER: TREATMENT DESCRIPTION AND
PRELIMINARY RESULTS OF A PHASE I/II CLINICAL TRIAL
YASUO YOSHIOKA, M.D.,* TAKAYUKI NOSE, M.D.,† KEN YOSHIDA, M.D.,* TAKEHIRO INOUE, M.D.,*
HIDEYA YAMAZAKI, M.D.,‡ EIICHI TANAKA, M.D.,* HIROYA SHIOMI, M.D.,* ATSUSHI IMAI, M.D.,*
SATOAKI NAKAMURA, M.D.,* SHIGETOSHI SHIMAMOTO, M.D.,* AND TOSHIHIKO INOUE, M.D.*
*Division of Multidisciplinary Radiotherapy, Biomedical Research Center, and ‡Department of Diagnostic Medicine, Osaka University
Graduate School of Medicine, Suita, Osaka, Japan; †Department of Radiation Oncology, Osaka Medical Center for Cancer and
Cardiovascular Diseases, Osaka, Japan
Purpose: To improve results for localized prostate cancer, a prospective clinical trial of hyperfractionated
Iridium-192 high-dose-rate (HDR) brachytherapy as a monotherapy was initiated.
Methods and Materials: Between May 1995 and September 1998, 22 implants were performed on 22 patients with
localized prostate cancer (T1:T2:T3:T4 5 4:6:9:3) at Osaka University Hospital. Nineteen patients, who had
T3-T4 tumors or pretreatment PSA > 20.0 ng/mL, received hormone therapy. No patient had external beam
radiation. Transperineal needle implants using real-time ultrasound guidance were performed, followed by dose
optimization program. Patients were irradiated twice a day, with a time interval of more than 6 h. Total dose was
48 Gy/8 fractions/5 days or 54 Gy/9 fractions/5 days. Acute toxicity was scored using the Radiation Therapy
Oncology Group (RTOG) radiation morbidity scoring criteria. Median follow-up time was 31 months.
Results: HDR brachytherapy as a monotherapy was well-tolerated. No significant intra- or peri-operative
complications occurred. No patient experienced acute toxicity of grade 3 or more. PSA levels normalized in 95%
of patients within 20 months after irradiation. Four-year clinical and biochemical relapse-free rates were 95%
and 55%, respectively.
Conclusion: Acute toxicity with this method was acceptable. Further patient accrual and longer follow-up will
allow comparison to other techniques. © 2000 Elsevier Science Inc.
Prostate cancer, Brachytherapy, High-dose-rate, Hyperfractionated, Monotherapy.
INTRODUCTION
Historically, low-dose-rate (LDR) brachytherapy for
early prostate cancer has achieved good clinical local con-
trol rates (1, 2). It is reasonable to expect the same, or even
better, results with ultrasound-guided high-dose-rate (HDR)
treatment regimens, having the potential advantages as fol-
lows: (a) homogeneous dose distribution using an optimi-
zation program, (b) good tumor coverage even in cases with
extracapsular invasion or bladder neck invasion, and (c)
complete radiation protection for staff and no need for
shielding the patient. The safety of HDR brachytherapy is
being established in many reports (3–5); however, it is
adopted only as a boost in almost every report. If we include
external beam irradiation, the dose of brachytherapy has to
be reduced to prevent adverse effects, which spoils the
advantage of brachytherapy that enables us to deliver an
increased dose to the local lesion. It is possible for HDR
brachytherapy to cover the locally advanced tumor with
enough dose by dwelling sources at the extracapsular posi-
tion, or even in the bladder pouch; therefore, the supple-
mental external beam irradiation is not essential. In this
philosophy, we planned HDR brachytherapy as a mono-
therapy to the localized prostate cancer without external
beam irradiation.
METHODS AND MATERIALS
Patient characteristics and selection
Between January 1994 and September 1998, 28 patients
with prostate cancer were treated with interstitial brachy-
therapy. Twenty-two of 28 patients met strict protocol-entry
criteria and are the subject of this report.
Protocol eligibility included the following: (a) having
clinical TNM stage T1-T3 and a part of T4 tumor (bladder
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neck invasion) without nodal metastasis or other distant
metastasis by clinical, biochemical, and imaging studies,
including all MRIs, CTs, and bone scans in all patients; (b)
patients had to be candidates for epidural anesthesia; (c) a
pretreatment transrectal ultrasound and serum prostate-spe-
cific antigen (PSA) level were required in all patients; and
(d) informed consent was mandatory. Patients were consid-
ered nonprotocol for various reasons, including: (a) prior
pelvic radiotherapy for another malignancy, (b) prior sur-
gery/TUR-P (transurethral resection of prostate) to prostate
gland, and (c) prostate cancer recurrence. Nonprotocol pa-
tients will not be considered further in this report.
The median age at diagnosis was 69 years (range 45–81).
All patients had biopsy-proven adenocarcinoma of the pros-
tate. Four patients had well-differentiated adenocarcinoma,
10 patients had moderately-differentiated adenocarcinoma,
and 8 patients had poorly-differentiated adenocarcinoma.
Using UICC TNM classification of 1997, 4 patients were
classified as T1, 6 patients as T2, 9 patients as T3, and 3
patients as T4. The pretreatment PSA level ranged from 7.0
to 150.0 ng/mL (median 30.9 ng/mL), including 2 cases
with 4.0–9.9 ng/mL, 6 cases with 10.0–19.9 ng/mL, and 14
cases with 20.0 ng/mL or more.
Hormonal therapy
The patients whose T-stages had been T1-T2 and pre-
treatment PSA levels , 20.0 ng/mL were treated with
radiotherapy alone (3 patients). The others (patients whose
T-stages had been T3-T4 or whose pretreatment PSA lev-
els $ 20.0 ng/mL) received neoadjuvant and adjuvant hor-
monal therapy (19 patients) (6). Neoadjuvant hormonal
therapy was based on maximum androgen blockade includ-
ing LH-RH agonist (leuprorelin acetate or goserelin acetate)
and antiandrogen (chlormadinone acetate or flutamide).
Leuprorelin acetate was given at a dosage of 3.75 mg s.c.
every 4 weeks, and 125 mg flutamide was given orally three
times daily. If ineffectiveness or adverse effects were ob-
served, leuprorelin acetate was changed to 3.6 mg goserelin
acetate and/or flutamide was changed to 50 mg chlormadi-
none acetate orally twice daily. In the 5 days of brachyther-
apy treatment, all hormonal therapy was interrupted. After
brachytherapy was completed, LH-RH agonist was re-
started, while antiandrogen was discontinued. The subgroup
whose T-stage had been T1-T2 and whose PSA levels
reached less than 0.7 ng/mL (which was the minimal de-
tectable value in our institution) discontinued all hormonal
therapy unless they hoped to continue it. As for the other
patients, only LH-RH analog was administered, unless the
patient refused it. If the biochemical failure was confirmed,
antiandrogen was restarted with or without starting other
hormonal therapy or chemotherapy.
Treatment technique
Brachytherapy was performed under epidural anesthesia.
At the time of operation, the patient was placed in a dorsal
lithotomy position, with the hips flexed as much as possible,
and the perineal region was prepared and draped in the usual
sterile fashion. A balloon catheter was inserted into the
bladder with iodinated contrast in the balloon. The bladder
was distended with 100-cc sterile saline. A stepper carriage
with an acrylic rectangular template attached was mounted
to the operating room table via an arm with locking univer-
sal joints. The template (TAISEIMEDICAL, Osaka, Japan)
has 88 needle holes spaced at 5-mm intervals without dis-
turbing the passage of the ultrasound probe. The ultrasound
probe (mechanical radial scanner, ASU-64Bt, ALOCA,
Tokyo, Japan) was connected to the template/stepper car-
riage and the intrarectal portion was covered with a standard
condom. The probe was inserted into the rectum and ma-
neuvered in such a way as to place the template in contact
with the perineum. The probe was manipulated to obtain the
best possible ultrasound image, without undue compression
of the posterior prostate. The fixation device was locked and
only longitudinal (superior-inferior) movement was permit-
ted thereafter. A series of transverse views of these levels
was measured and stored. The depth of probe insertion was
marked for distal end of the seminal vesicle, the base, the
apex, and the largest cross-section of the prostate gland
(called the midgland). Prior to needle placement, the probe
was placed at the midgland and the contours of the prostate
and seminal vesicle were outlined. The target volume of the
implantation was the prostate gland with or without the
medial aspects of the seminal vesicle. The medial aspect
was defined as a medial half of the seminal vesicle, which
was visualized on transrectal ultrasound (TRUS) in the
dorsal direction of the prostate gland and the bladder neck
up to 20 or 30 mm cranial from the base of the prostate
gland. The target volume was the prostate alone in T1 cases
and in the majority of T2 cases, while in T3 or T4 cases, and
in a part of T2 cases with suspected seminal vesicle micro-
invasion, the target volume involved the medial aspect of
the seminal vesicle other than the prostate, including the
extracapsularly invaded area. To ensure adequate implanta-
tion of the medial aspects of the seminal vesicles, these were
imaged by ultrasound, and needle placement was docu-
mented (Fig. 1). Metallic markers were implanted in the
apex, the distal end of the seminal vesicle, and critical point
for each patient to visualize on a roentgenogram. The me-
tallic needles (Trocar Point Needlest, Nucletron, The Neth-
erlands) were inserted to 10 mm cephalad to the prostate
and seminal vesicles. As each needle was placed, it was
identified by its template coordinates (3).
After all of the needles were placed under ultrasound
guidance, the patient was taken to the simulation room,
where roentgenograms were taken with dummy sources
packed in the needles. A CT scan was then performed to
ensure the relationship between needles and the prostate,
seminal vesicles, bladder, rectum, and bowels. The radi-
ation oncologists determined areas of source dwell on the
roentgenograms and the CT. Physicists reconstructed the
actual location of each needle by recognizing the dummy
sources on the roentgenograms, and optimized dwell
weights (Fig. 1). The rectal and bladder dose was also
calculated.
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Patients were restricted to bed for 5 days, from Monday
to Friday, and irradiated twice a day, with an interval of at
least 6 h between irradiation (Fig. 2). The treatment
consisted of (a) 8 fractions of 6.0 Gy each, 48 Gy in total,
in the first 7 cases, and (b) 9 fractions of 6.0 Gy each, 54
Gy in total, to the prostate in the latter 15 cases. Epidural
anesthesia was continued to the last day of irradiation
(for 5 days). Prophylactic antibiotic was administered
twice daily from the day of implant through day 7. To
suppress defecation, the patients were given low-resid-
uum meals from 4 days before implant to the last day of
irradiation and morphine chloride 20 – 40 mg orally three
Fig. 1. (a) TRUS showing the prostate enclosed by a superimposed line at the largest cross-section of the prostate and
the seminal vesicle. The superimposed square dots represent some of the grids in the template. The open circles indicate
the places where the needles were actually implanted in this case. (The actual intervals of needles were 5 or 10 mm.)
(b) The isodose plots of the same plane with (a). The arrow indicates the prescribed dose point and the curve crossing
it indicates the prescribed dose line.
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times daily from the day of implant to the last day of
irradiation.
Follow-up and toxicity analysis
Follow-up was performed by the radiation oncologist and
urologist at least once a month. Digital rectal examination
was performed every time. PSA level was examined
monthly and MRI every 6 months during follow-up in all
patients. Biochemical failure was defined as three times
successive elevation of PSA levels from nadir of PSA after
treatment, and the date of failure was defined as the mid-
point between the postirradiation nadir PSA and the first of
three consecutive rises (7). PSA was examined by AIA-
PACK PA (TOSOH, Japan), and the normal range was
defined as 2.1 ng/mL or less in this report.
Acute and chronic toxicities were scored using Radiation
Therapy Oncology Group (RTOG) guidelines (8). Acute
toxicity was defined as those symptoms that presented dur-
ing or after treatment that completely resolved by 6 months
post-treatment. Acute toxicity was graded according to the
most severe reaction observed. Treatment-related toxicities
that persisted or presented beyond 6 months following treat-
ment completion were considered chronic.
Statistical methods
Clinical local control and biochemical control rates were
calculated by the method of Kaplan and Meier (9).
RESULTS
Feasibility
All patients who started this treatment completed all
courses of the regimen. Although some patients complained
of lumbago due to continuous lying in bed during the course
of treatment, it was controllable and did not interrupt the
treatment regimen. Three patients felt numbness at the right
or left leg due to the continuous epidural anesthesia, which
was resolved easily by decreasing the dose of anesthetic,
and did not interrupt the treatment regimen. In some cases,
defecation in the treatment course was experienced, which
did not disturb the treatment.
Acute toxicity analysis
The median follow-up time was 31 months (range 19–
58). No significant intraoperative or perioperative compli-
cations that required treatment modification occurred. Tox-
icity of grade 3 or more was not observed in any patient.
Grade 2 acute toxicities were experienced in 8 (36%) pa-
tients a few days after treatment; all of them healed without
special treatment (Table 1). The number of patients with
grade 1 acute toxicity-alone was 3 (14%). All of the patients
who had gastrointestinal toxicities (4 patients) also had
grade 1 genitourinary toxicities. The total number of pa-
tients that showed any grade of acute toxicities was 11
(50%). Table 2 presents in detail the acute toxicity encoun-
tered with this treatment approach. We did not consider the
temporary event of hematuria, during or just after implan-
tation or detachment of the needles, which was caused by
mechanical stimulation of the needles and recovered with-
out treatment in a few hours, as acute radiation toxicity.
Chronic toxicity
Grade 2 rectal ulcer was experienced in one case 22
months after brachytherapy, and occasional grade 1 rectal
Fig. 2. Treatment schedule. The patients received a total dose of 54 Gy/9 fractions/5 days (from Monday to Friday)
under continuous epidural anesthesia. The time interval between the irradiation is at least 6 h.
Table 1. Acute toxicity results (n 5 22)
Gastrointestinal Genitourinary Overall
Grade 5 0 0 0
Grade 4 0 0 0
Grade 3 0 0 0
Grade 2 3 (14%) 5 (23%) 8 (36%)
Grade 1 1 (5%) 6 (27%) 6 (27%)
Total 4 (18%) 11 (50%) 11 (50%)
Grade: RTOG acute radiation morbidity scoring criteria.
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bleeding has been reported in another case since 24
months after brachytherapy. Impotence was estimated in
only 5 patients, because all other patients had lost po-
tency before brachytherapy due to aging or could not be
estimated due to continuing adjuvant hormonal therapy.
Two patients, who had not received hormonal therapy,
have kept potency after brachytherapy thus far (24 and 55
months post-brachytherapy, respectively). Another two
patients, who had received neoadjuvant and adjuvant
hormonal therapy and then discontinued adjuvant hor-
monal therapy, recovered potency (21 and 36 months
post-brachytherapy, respectively). One patient lost po-
tency after brachytherapy; however, the time when he
lost potency had been masked by 5 months of neoadju-
vant hormonal therapy and 1 month of adjuvant hormonal
therapy. No other chronic toxicity, such as incontinence
or urethral narrowing has been observed thus far.
Rectal and urethral dose calculations
The dose irradiated for urethra distributed between 54
and 81 Gy (for the group irradiated with a total dose of 54
Gy).
The dose irradiated for anterior surface of rectal mucosa
was under the prescribed dose (54 Gy) in all cases.
Irradiated volume
The median number of needles placed was 16 (range
8–18). Median V100 (100% isodose volume) was 55.7 cm3
(range 28–82 cm3), and median V200 (200% isodose vol-
ume) was 5.0 cm3 (range 2.3–7.4 cm3). All cases that had
more than 60 cm3 irradiated volume resulted in grade 1 or
2 complications (Fig. 3).
Clinical local control
All 22 patients were controlled locally; that is, no evi-
dence of tumor was detected either on digital-rectal exam-
ination or on MRI. One case developed multiple bone
metastasis 7 months after the treatment but showed no
evidence of local recurrence.
Biochemical control
Biochemical control rate was shown in Fig. 4, excluding
one patient who developed multiple bone metastasis. Two-,
three-, and four-year control rates were 65%, 55%, and
55%, respectively.
In 22 patients, 19 patients had been treated with hor-
mone therapy before HDR brachytherapy. In this group,
the median pretreatment PSA level had been 48.2 ng/mL
(range 7.2–150.0), and the median span of the neoadju-
vant hormonal therapy was 7 months (range 1–19). PSA
levels had been normalized before brachytherapy in 12 of
19 cases. In the remaining 7 cases, PSA levels had not
been normalized by neoadjuvant hormone therapy but
normalized by brachytherapy in 6 cases, while one case
did not reach the normal range. The time to PSA nadir
after HDR brachytherapy ranged from 1 to 20 months
(median 9). Four patients stopped adjuvant hormonal
therapy after the median span of 14 months of adjuvant
hormonal therapy (range 1–32), and the other 15 patients
continued adjuvant hormonal therapy.
Three patients were treated with HDR brachytherapy-
alone without hormone, and their PSA levels were all nor-
malized after HDR brachytherapy. Their pretreatment PSA
levels were 7.0, 18.6, and 19.3 ng/mL, respectively, and the
time to PSA nadir after HDR brachytherapy was 6, 15, and
14 months, respectively.
DISCUSSION
To improve the local control rate after radiotherapy, dose
escalation is a reasonable approach because dose response
relationship for radiotherapy exists (10, 11). However, an
increased external beam irradiation dose will at the same
time increase the toxicity rate (10, 11), and the organ motion
Table 2. Contents of acute toxicities
Grade 3 or more None
Grade 2 2* Dysuria
2 Rectal pain
1 Perineal pain
1 Increased urinary frequency/urgency
1 Gross hematuria†
1 Urinary tract infection
Grade 1 5 Increased urinary frequency/urgency
3 Urinary retension
1 Dysuria
1 Rectal pain
1 Hematuria‡
* The total number exceeds that of Table 1 because some
patients revealed multiple events.
† Temporary gross hematuria needed medication.
‡ Temporary hematuria without need for medication.
Fig. 3. Relationship between acute complications and irradiated
volumes. All cases that had more than 60 cm3 irradiated volumes
resulted in grade 1 or 2 complications.
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makes it difficult to shrink the field size for reducing ad-
verse effects (12).
Interstitial brachytherapy has the potential to solve this
problem; that is, it enables us to administer higher dose in a
small volume (the prostate), and to spare the adjacent struc-
tures due to rapid dose fall-off outside the target volume.
Past experience using LDR prostate implantation has
resulted in good pathologic and clinical local control rates
(1, 2), but not satisfactory ones in the locally advanced or
high-risk cases, which may be attributed to inhomogeneous
dose distribution and insufficient tumor covering. It is rea-
sonable to expect the same, or even better, results with
ultrasound-guided HDR treatment regimens, because it has
achieved homogeneous dose distribution by an optimization
program, the rigidity of metallic needles to grasp the target
leads to the preservation of the calculated dose distribution
throughout the treatment period. It is difficult to estimate the
actual irradiated dose in LDR brachytherapy because of
post-implant edema of the prostate, which may have a
significant effect on the post-implant dosimetry (13). It is
also difficult to estimate the actual irradiated dose in exter-
nal beam radiotherapy because of the daily variability of the
position of the prostate (12). The HDR needle implantation
technique also has advantages over seed implantation in the
area of tumor coverage, because the treatment source can be
delivered deep enough to cover the margin of the target,
moving freely into the needles even in the extracapsular
tissue or in the bladder pouch.
On the other hand, according to the current radiobiolog-
ical theory, HDR has a disadvantage of a lower therapeutic
ratio, and the short overall treatment time of 5 days would
disadvantageously affect treatment of the prostate cancer.
However, the advantages of HDR brachytherapy in radia-
tion physics mentioned above possibly compensate for such
radiobiological disadvantages.
In the treatment of T3-T4 prostate cancer, in which
radical prostatectomy or LDR brachytherapy may be a
contraindication because of the incapability to treat extra-
capsularly invasive tumor, the combination of HDR brachy-
therapy and hormonal therapy may be considered as one of
the possible radical therapies. Supplemental hormonal ther-
apy may enhance the effect of radiotherapy without limiting
it, while the supplemental external beam radiotherapy
would limit the total dose of brachytherapy (6).
The results presented in this report indicate acceptable
short-term tolerance to the radiation doses delivered by our
technique using hyperfractionated HDR Iridium-192
brachytherapy as a monotherapy. The treatment-related tox-
icities were primarily gastrointestinal and genitourinary in
nature and were, as expected, less than a course of whole
pelvis external irradiation. It was an encouraging result that
no patient showed acute toxicity of grade 3 or more. How-
ever, the irradiated volume of more than 60 cm3 may highly
predict grade 1 or 2 acute toxicity in our method. As for
chronic toxicities, the low rate of rectal bleeding or impo-
tence, and the fact that no patient has revealed incontinence
or urethral narrowing is expected, although the follow-up
time is too short for estimation.
The local tumor response in this series as assessed by
serial PSA measurements after irradiation and clinical ex-
aminations appears encouraging, although further patient
accrual and longer follow-up are necessary to confirm these
Fig. 4. Kaplan-Meier plot of clinical NED (no evidence of disease) rate and biochemical NED rate. The one patient who
developed multiple bone metastasis without local recurrent signs was excluded. Two-, three-, and four-year biochemical
NED rates were 65%, 55%, and 55%, respectively.
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results. The rate of PSA normalization (95%) in our
results is highly encouraging, considering that our pa-
tients include many T3-T4 or high pretreatment PSA
level ($ 20 ng/mL) cases (82%), which may unfavorably
affect PSA normalization rates. However, it must be
taken into consideration that we used hormone as a
neoadjuvant for the patients whose pretreatment PSA
levels were 20.0 ng/mL or more until PSA levels were
reduced to less than 20.0 ng/mL. And we also used
hormone for all T3-T4 patients. The 6 cases whose PSA
levels had not been normalized by hormone but were
normalized by brachytherapy, and the 3 cases whose PSA
levels were normalized by brachytherapy alone, suggest
the early efficacy of this treatment regimen even without
adding hormone. The present report also adds to the
paucity of information regarding PSA normalization fol-
lowing irradiation treatment approaches that use HDR
brachytherapy as a monotherapy.
CONCLUSION
Acute toxicity in 22 patients treated with this unique
approach, using HDR brachytherapy without external beam
irradiation, has been acceptable within the established pro-
tocol guidelines. The initial tumor response, as assessed by
PSA measurement, appears promising and further patient
accrual and follow-up are necessary to determine local
control, biochemical control, survival, and chronic toxicity
rates with this treatment regimen. If acceptable local control
and toxicity rates are observed, we plan to conduct a Phase
III randomized study to compare this treatment approach
with conformal external beam irradiation for locally ad-
vanced prostate cancer.
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